Immunology
Inspired by the promise of helping patients reclaim their lives, we strive to deliver transformational and accessible therapies for patients with conditions in rheumatology, dermatology and gastroenterology.
Our commitment to patients
Johnson & Johnson is committed to alleviating the lifelong challenges faced by those with immune-mediated inflammatory diseases.
Our goal is to improve the diagnosis of immune-mediated inflammatory diseases, improve patients’ access to the best possible treatments and continue to provide new and better medicines.
Our goal is to improve the diagnosis of immune-mediated inflammatory diseases, improve patients’ access to the best possible treatments and continue to provide new and better medicines.
We recognize the profound impact of Immune-Mediated Diseases
People living with immune-mediated inflammatory diseases can be affected for the rest of their lives, yet the impact of these conditions is dramatically underestimated. As some of these diseases are not readily recognised, people can suffer silently before eventually receiving treatment.
Our treatment areas
We are proud to have one of the strongest treatment portfolios for some of the most common immune-mediated inflammatory diseases.
-
Dermatology
Our focus in dermatology is on the inflammatory skin condition psoriasis. -
Rheumatology
Our focus in Rheumatology is currently inflammatory disorders of the joints and skin: Psoriatic Arthritis, Rheumatoid Arthritis (RA) and Axial Spondyloarthritis (AxSpA). -
Gastroenterology
Our focus in Gastroenterology is inflammatory bowel disease: Crohn’s disease and Ulcerative colitis.
Our pioneering breakthroughs change lives
We’ve always been innovative in our science, finding new and more effective ways to transform the course of immune-mediated inflammatory diseases and calm the inner battle waging within patients’ bodies.
Since the advent of targeted biologic therapy over 35 years ago, we developed the first licensed monoclonal antibody to act directly on the immune system, providing patients with an unprecedented level of efficacy and symptomatic relief.1
Since the advent of targeted biologic therapy over 35 years ago, we developed the first licensed monoclonal antibody to act directly on the immune system, providing patients with an unprecedented level of efficacy and symptomatic relief.1
We will continue our search for more advanced and effective medicines
We remain committed to developing better therapies with the goal of stopping or even curing immune-mediated inflammatory diseases, especially where significant unmet needs persist.
Working together to achieve a world where immune-mediated inflammatory diseases are a thing of the past
Our commitment to immune-mediated inflammatory diseases goes beyond our medicines. We support patients through collaborations with patient advocacy organisations.
We invest heavily in continuous medical education of doctors and care providers, uniting different therapeutic areas to share expertise and best practices.
We invest heavily in continuous medical education of doctors and care providers, uniting different therapeutic areas to share expertise and best practices.
Even though we have made great progress in the last decade for the treatment of immune-mediated inflammatory diseases, our work aims to raise the bar to make periods of disease remission more durable and allow patients with these debilitating diseases to lead normal lives.
Ludovic de Beaucoudrey, PhD
JANSSEN THERAPEUTIC AREA LEAD, IMMUNOLOGY, EUROPE, MIDDLE EAST & AFRICA
Apsolutely.be
If you want to learn more about psoriasis or psoriatic arthritis, check out Apsolutely, our online patient portal for people living with psoriatic disease or who are interested in learning more about the disease.
You are now leaving the jnj.innovativemedicine.com website.
We inform you that the privacy policy on the external site may be different from the jnj.innovativemedicine.com website.
References
[1] Liu JK. The history of monoclonal antibody development - Progress, remaining challenges and future innovations. Ann Med Surg (Lond). 2014;3(4):113-116
© Janssen-Cilag NV/B.V., a Johnson&Johnson company – CP-490851 – Approval date: 11-2024, vu/er Luc Van Oevelen, Antwerpseweg 15-17, 2340 Beerse